Milestone Pharmaceuticals Inc (MIST) concluded trading on Wednesday at a closing price of $2.01, with 5.48 million shares of worth about $11.02 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 30.94% during that period and on March 26, 2025 the price saw a gain of about 6.91%. Currently the company’s common shares owned by public are about 53.35M shares, out of which, 50.79M shares are available for trading.
Stock saw a price change of 1.01% in past 5 days and over the past one month there was a price change of 11.67%. Year-to-date (YTD), MIST shares are showing a performance of -14.83% which increased to 15.52% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.12 but also hit the highest price of $2.75 during that period. The average intraday trading volume for Milestone Pharmaceuticals Inc shares is 1.32 million. The stock is currently trading 3.74% above its 20-day simple moving average (SMA20), while that difference is up 0.17% for SMA50 and it goes to 18.54% higher than SMA200.
Milestone Pharmaceuticals Inc (NASDAQ: MIST) currently have 53.35M outstanding shares and institutions hold larger chunk of about 42.45% of that.
The stock has a current market capitalization of $107.25M and its 3Y-monthly beta is at 1.09. It has posted earnings per share of -$0.72 in the same period. It has Quick Ratio of 9.10 while making debt-to-equity ratio of 4.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MIST, volatility over the week remained 10.47% while standing at 11.33% over the month.
Stock’s fiscal year EPS is expected to drop by -80.60% while it is estimated to decrease by -4.96% in next year. EPS is likely to shrink at an annualized rate of 2.38% for next 5-years, compared to annual growth of 28.21% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on August 22, 2024 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by Jefferies stated Milestone Pharmaceuticals Inc (MIST) stock as a Hold in their note to investors on June 20, 2023, suggesting a price target of $4 for the stock. On April 22, 2022, Piper Sandler Upgrade their recommendations, while on March 05, 2021, H.C. Wainwright Initiated their ratings for the stock with a price target of $20. Stock get an Outperform rating from Oppenheimer on July 29, 2020.
